Infectious Diseases Unit, Hospital de la Santa Creu I Sant Pau, Univeristat Autònoma de Barcelona, Av. Sant Antoni Mª Claret, 167, 08025 Barcelona, Spain.
Expert Opin Drug Saf. 2012 May;11(3):473-85. doi: 10.1517/14740338.2012.676639. Epub 2012 Apr 3.
The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries. This review is intended to assess the benefits and risks in terms of safety of d4T + 3TC-based combination antiretroviral therapy (ART) for the treatment of HIV-1 infection.
The most relevant papers related to the safety of d4T + 3TC-based ART were selected and summarized.
In industrialized countries, the 3TC + d4T combination is not recommended for initial therapy because of long-term metabolic toxicities associated with d4T. In developing countries, it may have a role in the treatment of HIV-infected patients if there is no other chance for starting antiretroviral therapy.
拉米夫定（3TC）+司他夫定（d4T）联合治疗方案在资源匮乏国家中仍广泛用于一线治疗 HIV-1 感染患者。本综述旨在评估以 d4T+3TC 为基础的联合抗逆转录病毒治疗（ART）在治疗 HIV-1 感染方面的安全性和益处。
选择和总结了与 d4T+3TC 为基础的 ART 安全性最相关的论文。
在工业化国家，由于与 d4T 相关的长期代谢毒性，不推荐将 3TC+d4T 联合治疗方案用于初始治疗。在发展中国家，如果没有其他开始抗逆转录病毒治疗的机会，它可能在治疗 HIV 感染患者方面发挥作用。
